Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics is a clinical-stage biotechnology company based in New York, NY, that develops therapies for patients with severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody designed to selectively bind to active C1s, a complement protein. Dianthus is conducting clinical trials of claseprubart in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Its second clinical-stage candidate, DNTH212, is a fusion protein that targets BDCA2 and inhibits BAFF/APRIL. Dianthus licenses claseprubart development and commercialization rights in Greater China to Tenacia Biotechnology. It holds rights to its product candidates outside Greater China, including through exclusive licenses, and contracts with third parties to manufacture and distribute them.
No enriched coverage for $DNTH in the last 7 days.
Savitz Ryan (EVP, CFO & CBO) sold 124,042 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $90.52 ($85.16–$91.59, $11.23M total) across 9 trades over 2026-11-09 to 2026-11-12 under a Rule 10b5-1 trading plan.
Raymond James raised its price target for Dianthus Therapeutics (DNTH) to $134 from $131, maintaining a Strong Buy rating. The biotech company's shares are up 108% year-to-date and 154% over the past year. The firm cited clinical advancements and upcoming study readouts. Analysts have mixed price targets, ranging from $113 to $200, with some suggesting the stock may be overvalued.
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q3 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized
Recent DNTH coverage spans financial news, insider activity and earnings.
In the last 30 days, DNTH insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($11.2M). The most active reporter was Savitz Ryan, EVP, CFO & CBO, with 9 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal reduced confidence and could pressure the stock lower.
Analyst price target increase suggests upside potential.
The disclosure provides fresh financials and trial timelines for a micro‑cap biotech, likely prompting modest price movement.
The update may modestly support DNTH share price by confirming continued development milestones, but no immediate catalyst for a sharp move.
Near-term trading should hinge on whether Q3 results and any cash runway or burn-rate commentary align with expectations, ahead of trial-data milestones.
AlphAI scores every news story that mentions DNTH with an AI model for sentiment and relevance, and aggregates insider trades from Dianthus Therapeutics, Inc. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Savitz Ryan (EVP, CFO & CBO) sold 124,042 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $90.52 ($85.16–$91.59, $11.23M total) across 9 trades over 2026-11-09 to 2026-11-12 under a Rule 10b5-1 trading plan.
Raymond James raised its price target for Dianthus Therapeutics (DNTH) to $134 from $131, maintaining a Strong Buy rating. The biotech company's shares are up 108% year-to-date and 154% over the past year. The firm cited clinical advancements and upcoming study readouts. Analysts have mixed price targets, ranging from $113 to $200, with some suggesting the stock may be overvalued.
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q3 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized
Dianthus Therapeutics (DNTH) reported $1.2B in cash to fund operations into 2030. Claseprubart, its lead drug, is in Phase 3 trials for gMG (results 2H’28), CIDP (Part A results YE’27, Part B YE’28), and MMN (Phase 2 results December ’26). DNTH212 and DNTH312 are advancing in early-stage trials. The company aims to initiate a Phase 3 MMN trial in 2027.
Dianthus Therapeutics (DNTH) is set to report Q3 earnings, with analysts expecting a loss of $0.94 per share on revenue of $443,850. The stock has a strong buy consensus and a mean price target of $139.06, implying 68% upside. Investors will focus on pipeline updates, including Phase 2 trial data for MMN and Phase 3 enrollment guidance for CIDP. The company has a cash balance of $1.19 billion, providing runway into 2030.
Dianthus Therapeutics (DNTH) stock rose 0.8% in after-hours trading to $80, following Roth/MKM's Buy rating and $113 price target. The company has 18 Buy ratings with no Holds or Sells, and targets up to $158. Next earnings are scheduled for November 5.
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
CARR EDWARD (CHIEF ACCOUNTING OFFICER) sold 20,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.38 ($100.43–$104.39, $2.03M total) across 5 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
Analysts initiated coverage on five companies: Keybanc rated PPG Industries (PPG) Overweight with a $133 target, Bernstein rated Shopify (SHOP) Outperform with a $160 target, Mizuho rated Chesapeake Utilities (CPK) Outperform with a $150 target, Piper Sandler rated Global Payments (GPN) Neutral with a $101 target, and JP Morgan rated Dianthus Therapeutics (DNTH) Overweight with a $135 target. All stocks closed lower than their respective targets on Thursday.
Analysts initiated or updated coverage on several companies. Piper Sandler initiated Q2 Holdings as overweight, citing its growth potential. Bernstein initiated Shopify as outperform, highlighting its AI positioning. RBC initiated Dell as outperform with a $640 price target, citing AI infrastructure demand. UBS initiated Korsana Biosciences as buy with a $55 price target. Other notable mentions include Nvidia, SpaceX, Tesla, Palantir, and Oracle.
